Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02972502 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department
A Phase 4 study, sponsored by OhioHealth.
- Terminated
- Registry status
- Phase 4
- Development phase
- 66
- Enrollment target
NCT02972502: Clinical Trial Phase 4 study, sponsored by OhioHealth.
NCT02972502 is a Phase 4 study that was terminated before completion, run by OhioHealth. The registered enrollment target is 66 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02972502, a Phase 4 study, was terminated before completion, sponsored by OhioHealth.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 66 participants
- Enrollment target
Study Summary
Metoclopramide (Reglan) is a common agent used for relief of headaches in the emergency department (ED).In this study the investigators seek to explore another option for treatment of headaches in the ED, one that may be more efficacious and efficient. Haloperidol (Haldol), a butyrophenone class of medication, is thought to act by affecting the dopamine 2 receptor in the brain. By exploring haloperidol as an option for treatment, the investigators hope to discover a more efficient and effective medication for the treatment of non-traumatic headaches, thereby decreasing a patient's length of stay in the department and decreasing the rate of return visits for continued discomfort from the same headache. This study could lead to the increased usage of haloperidol as a first line agent in the treatment of prolonged headaches presenting to the ED.
Primary Outcome
Numeric Pain Intensity scale is a standard rating tool for pain, ranging from 0-10, with 0=no pain and 10=worst pain imaginable.
Interventions
- DRUG Haloperidol
- OTHER Normal Saline
- DRUG Diphenhydramine
- DRUG Metoclopramide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2014-02 |
| Est. Completion | 2017-04-24 |
| Phase | Phase 4 |
Why NCT02972502 stopped before completion
NCT02972502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 4 interventions - of which Haloperidol is the first listed.
NCT02972502 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02972502 about?
NCT02972502 is a clinical study titled "Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department". Metoclopramide (Reglan) is a common agent used for relief of headaches in the emergency department (ED).In this study the investigators seek to explore another option for treatment of headaches in the ED, one that may be more efficacious and efficient. Haloperidol (Haldol), a butyrophenone class of ...
What is the current status of trial NCT02972502?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 66 participants. The study started on 2014-02. Estimated completion is 2017-04-24.
What interventions are being tested in trial NCT02972502?
The interventions under investigation include: Haloperidol (DRUG), Normal Saline (OTHER), Diphenhydramine (DRUG), Metoclopramide (DRUG).
Who is sponsoring clinical trial NCT02972502?
This trial is sponsored by OhioHealth, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02972502's enrollment target sits among peer trials
66 1083rd of 2000 higher than 910 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia